Oxford Biomedica PLC Total Voting Rights (6991I)
September 01 2016 - 5:47AM
UK Regulatory
TIDMOXB
RNS Number : 6991I
Oxford Biomedica PLC
01 September 2016
Oxford BioMedica
Total Voting Rights
Oxford, UK - 1 September 2016: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, announces that in accordance with the FCA's
Disclosure and Transparency Rule 5.6.1, the Group's issued share
capital as at the close of business on 31 August 2016 consisted of
2,703,806,022 ordinary shares of 1 pence each ("Ordinary Shares").
There are no Ordinary Shares held in treasury.
Accordingly, the total number of voting rights in Oxford
BioMedica plc at the date of this notice is 2,703,806,022.
The above figure (2,703,806,022) may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, Oxford BioMedica plc under the FCA's Disclosure
and Transparency Rules.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
230 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREANNFELSKEEF
(END) Dow Jones Newswires
September 01, 2016 05:47 ET (09:47 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024